This document discusses the treatment of metastatic disease in lung cancer. It emphasizes the importance of determining histology (squamous vs. non-squamous) and biomarkers to guide treatment decisions. For squamous cell carcinoma, EGFR/ALK testing is not recommended and treatment involves platinum-based doublets or cetuximab-containing regimens. For non-squamous, testing for EGFR/ALK is recommended, and if negative, initial treatment with carboplatin/pemetrexed is an option. The prognostic value of TTF-1 is also discussed, as its negativity highly predicts EGFR mutation negativity. Treatment decisions should incorporate histology, biomarker status, and other clinical factors.